An observational study in Type 2 Diabetes and Poor Glycemic Control, sponsored by Goztepe Prof Dr Suleyman Yalcın City Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-26.
Sponsored by Goztepe Prof Dr Suleyman Yalcın City Hospital · Observational
In Turkey, only 55% of patients with type 2 diabetes have been diagnosed, and 91% of these patients have been receiving treatment. The rate of patients reaching the treatment target is 50%. The pandemic has also affected diabetic patients. It is aimed to determine the characteristics of patients with type 2 diabetes (HbA1c >=10) with poor metabolic control and to evaluate the extent to which metabolic control can be achieved in 12 months.
Patients who applied to Istanbul Medeniyet University Goztepe Prof. Dr. Suleyman Yalcin City Hospital Diabetes Polyclinics and have an HbA1c levels of >= 10% in their examinations will be admitted to the study. Detailed history, including medication usage and previous blood tests will be questioned. The patients will be asked to complete questionnaires about their eating patterns (mindful eating questionnaire), their physical activities (General practice physical activity questionnaire), and whether the participants have depression (Beck depression questionnaire). Anthropometric measurements will be taken, and biochemical data will be recorded. Patients will be grouped according to their previous HbA1c values as a) newly diagnosed, b) those whose diabetes was previously controlled, c) those whose diabetes was previously not at the target range but now worsened, and d) those whose diabetes was poorly controlled from the beginning. Diabetes follow-up will be continued by their respective physicians. The patients will be called again three months after their enrollment to record the most recent biochemical data. Patient characteristics (age, gender, educational status, depression status, eating awareness, exercise characteristics) will be evaluated in accordance with the predetermined HbA1c groups. Again, according to the patient groups, the difference in HbA1c after three months, the frequency of reaching the target, and possible factors associated with the findings will be evaluated.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 266 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Goztepe Prof Dr Suleyman Yalcın City Hospital is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who have been diagnosed
Exclusion Criteria:
Patients who have been diagnosed with type 2 diabetes within a month
Patients who had at least two HbA1c levels =\<%7,5 before enrollment
Patients who had at least two HbA1c levels between %7,5 and %9,49 before enrollment
Patients who had at least two HbA1c levels above %9,5 before enrollment
Changes in HbA1c levels after 12 months treatment
Changes in HbA1c levels after 12 months treatment according to the predetermined HbA1c groups.
Time frame: twelve months
percentage of patients who reached the HbA1c target of equal to or below 7%
Comparison of the patient groups in their success in reaching the HbA1c target of equal to or below 7%
Time frame: twelve months
The effect of education on the HbA1c changes
Educational status may have an impact on HbA1c reduction. Participants who have reached the HbA1c target are compared in terms of their educational level and those who have not.
Time frame: twelve months
The effect of depression on the HbA1c changes
The Beck Depression Index will be used to compare participants who reach the HbA1c target and those who do not
Time frame: twelve months
The effect of the level of physical activity on the HbA1c changes
Physical activity is graded into 4 levels. Levels will be compared in participants who reach target HbA1c level and who do not
Time frame: twelve months
The effect of weight loss on the HbA1c changes
The effect of weight loss on reaching HbA1c target of 7% will be compared
Time frame: twelve months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Goztepe Prof Dr Suleyman Yalcın City Hospital